Litigation

Recent Posts

Pa. Supreme Court Says Drug Companies Can Be Sued For Marketing Dangerous Drugs
Posted on 23 Jan 2014 by Tom Moylan

PHILADELPHIA — (Mealey’s) Pennsylvania law allows drug companies to be sued if they fail to stop marketing drugs known to be unreasonably harmful, and the manufacturers are not immune from being sued for damages for lack of due care, the Pennsylvania... Read More

Pa. High Court Reconsiders, Won’t Disturb $8.6M Prempro Punitive Damages Award
Posted on 17 Dec 2013 by Tom Moylan

PHILADELPHIA — (Mealey’s) The Pennsylvania Supreme Court on Dec. 16 let stand an $8.6 million punitive damages verdict in a Prempro hormone replacement therapy case after dismissing the appeal as improvidently granted ( Mary Daniel, et al... Read More

Pa. High Court: Drug Company Lacks Standing To Challenge State’s Outside Counsel
Posted on 18 Aug 2010 by Tom Moylan

PHILADELPHIA - (Mealey's) Janssen Pharmaceutica Inc. lacks standing under Pennsylvania law to challenge the hiring of outside counsel to represent the state in a Risperdal off-label marketing lawsuit, the Pennsylvania Supreme Court ruled Aug. 17 ... Read More

Pennsylvania Panel Reinstates Compensatory, Punitive Damages In Prempro Case
Posted on 8 Feb 2011 by Tom Moylan

PHILADELPHIA - A Pennsylvania Superior Court panel on Feb. 7 reinstated a $1.68 million compensatory damage verdict and a sealed punitive damage verdict in a state court Prempro case ( Mary Daniel, et al. v. Wyeth Pharmaceuticals, Inc., et al. , Nos.... Read More

Pa. Supreme Court Vacates $27.7M Drug Pricing Judgment Against Bristol-Myers
Posted on 17 Jun 2014 by Tom Moylan

HARRISBURG, Pa. — (Mealey’s) The Pennsylvania Supreme Court on June 16 vacated a $27.7 million drug pricing judgment against drug maker Bristol-Myers Squibb Co. (BMS) because a trial court failed to account for billions of dollars in drug... Read More

$4 Million Awarded In 1st Pa. Trial Alleging Birth Defect From Topamax Epilepsy Drug
Posted on 31 Oct 2013 by Tom Moylan

PHILADELPHIA — (Mealey’s) A Pennsylvania jury on Oct. 30 found that Janssen Pharmaceuticals Inc. failed to warn about the risk of birth defects from its Topamax epilepsy drug and awarded the injured minor $4 million in damages (April Czimmer... Read More

Pennsylvania Appeals Court Affirms $10M Children’s Motrin TEN Injury Verdict
Posted on 23 Jul 2014 by Tom Moylan

PHILADELPHIA — (Mealey’s) A Pennsylvania appeals court panel on July 22 affirmed a $10 million Children’s Motrin verdict for a girl who suffered toxic epidermal necrolysis (TEN) after being given the over-the-counter pain/fever reducer... Read More

Pennsylvania State Court Jury Awards $2.5 Million In Risperdal Gynecomastia Trial
Posted on 24 Feb 2015 by Tom Moylan

PHILADELPHIA — (Mealey’s) A Pennsylvania state court jury on Feb. 24 awarded $2.5 million to the family of a man who claimed that the atypical antipsychotic drug Risperdal caused gynecomastia, or enlarged male breasts ( P.P., et al. v. Ortho... Read More

Pennsylvania State Court Jury Awards $10 Million In 2nd Topamax Birth Defect Trial
Posted on 20 Nov 2013 by Tom Moylan

PHILADELPHIA — (Mealey’s) A Pennsylvania state court jury on Nov. 18 awarded more than $10 million to a family whose son was born with a cleft palate allegedly caused by his mother’s use of the antiepileptic drug Topamax during pregnancy... Read More

McNeil Pleads Guilty, Pays $25M For Making Adulterated Children’s Medicines
Posted on 11 Mar 2015 by Tom Moylan

PHILADELPHIA — (Mealey’s) The McNeil-PPC Inc. subsidiary of Johnson & Johnson on March 10 pleaded guilty to a federal misdemeanor criminal charge of making adulterated children’s over-the-counter medicines and agreed to pay a criminal... Read More

Pennsylvania State Court Jury Awards Plaintiff $2 Million In Actos Bladder Cancer Case
Posted on 6 Oct 2014 by Tom Moylan

PHILADELPHIA — (Mealey’s) A Pennsylvania state court jury on Oct. 3 awarded an Actos bladder cancer patient $2.05 million in economic and noneconomic damages but declined to award punitive damages ( Frances Wisniewski v. Takeda Pharmaceuticals... Read More

Janssen Settles Some Pa. Topamax Birth Defect Cases, Will Appeal $3M Verdict
Posted on 11 Mar 2014 by Tom Moylan

PHILADELPHIA — (Mealey’s) Topamax manufacturer Janssen Pharmaceuticals on March 10 said it will appeal a $3 million March 7 birth defect verdict in the Philadelphia County Common Pleas Court even though it reached an agreement to resolve a... Read More

U.S. High Court Denies Review Of Last Pending Appeal Of Generic Label-Update Claim
Posted on 18 May 2015 by Tom Moylan

WASHINGTON, D.C. — (Mealey’s) The U.S. Supreme Court on May 18 denied review in the last pending “failure-to-update-warnings” preemption appeal by generic drug manufacturers ( Teva Pharmaceuticals USA, Inc., et al. v. Paul E. Hassett... Read More